Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients

Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients

Multicenter double-blind placebo-controlled parallel-group randomized clinical trial of efficacy and safety of Raphamin in the treatment of coronavirus disease 2019 in outpatients.

Study Overview

• Status: Active, not recruiting
• Conditions: Coronavirus Disease 2019 (COVID-19)
• Intervention / Treatment: Drug: Raphamin; Drug: Placebo

Detailed Description

Design: multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial.

The study enrolls outpatients of either gender aged 18-75 years with increased body temperature > 37.5°C and other upper respiratory infection symptoms (cough, chest congestion, sore throat, nasal congestion/moderate rhinorrhea). A physician should specify the patient's status of vaccination for COVID-19, influenza and other infections. Patients within the first four weeks after any vaccination/booster vaccination are not considered as candidates to participate in the study.

Nasopharyngeal swabs and rapid COVID-19 test are made after signing informed consent (two versions are used: (1) for patients consented for laboratory tests; (2) for patients without the consent).

Patients with a positive rapid test and presence of mild COVID-19 (upper respiratory infection symptoms, no symptoms of moderate or severe forms) within 24 hours after manifestation of the first disease symptoms are considered as candidates for the study. Oxygen saturation (SpO2) is measured by pulse oximetry in all patients (pulse oximeters are provided by the study sponsor). If SpO2 is ≥95%, a patient may be selected for the study. Baseline severity for COVID-19 symptoms is evaluated using the scoring system "Assessment of 14 Common COVID-19-Related Symptoms" (FDA, 2020). This scoring system assesses the follows symptoms:

1. Stuffy or runny nose.
2. Sore throat.
3. Shortness of breath (difficulty breathing).
4. Cough.
5. Low energy or tiredness.
6. Muscle or body aches.
7. Headache.
8. Chills or shivering.
9. Feeling hot or feverish.
10. Nausea (feeling like you wanted to throw up).
11. Vomiting.
12. Diarrhea.
13. Sense of smell.
14. Sense of taste.

Each symptom is scored individually using the following scoring values:

• Items 1-10: None = 0; Mild = 1; Moderate = 2; and Severe = 3;
• Items 11 and 12: Not at all = 0; 1-2 times = 1; 3-4 times = 2; 5 or more times = 3;
• Items 13 and 14: Sense of smell/taste same as usual = 0; Sense of smell/taste less than usual = 1; No sense of smell/taste = 2.

The minimal baseline score for COVID-19-related symptoms is defined as follows: at least two symptoms with a score of 2 or higher, with the exception of taste and smell where subjects may have a score of 1 or higher, and the absence of shortness of breath (difficulty breathing).

If more severe symptoms are presented, the patient is not included in the study. The therapeutic approach is determined by the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)".

During the screening visit 1 (Day 1), in addition to rapid COVID-19 test and SpO2 measurement, patients are examined by a physician, nasopharyngeal swabs for PCR for SARS-CoV-2 and laboratory tests are performed.

Patients who meet all the inclusion criteria and do not have exclusion criteria at Visit 1 (Day 1) are randomized into one of two groups: patients in group 1 receive Raphamin for 5 days; patients in group 2 receive placebo according to the Raphamin regimen.

If positive PCR test is received (confirmation of new coronavirus disease COVID-19), the patient continues to participate in the study. If PCR result is negative, the patient completes participation in the study ahead of schedule, and his further therapy is determined by a doctor in accordance with the standard of care.

Electronic patient diary (EPD) is utilized in the study where morning and evening axillary temperature records are made with the time of measurement. The sponsor provides a classical mercury-free thermometer to each patient. In addition, presence and severity of the disease symptoms according to the scoring system "Assessment of 14 Common COVID-19-Related Symptoms", antipyretics administration and probable worsening of disease duration should also be recorded in EPD. All patients are provided with paracetamol. The physician instructs the patient how to fill in the diary. The EPD is available for filling in within 28 days of participation in the study.

Overall, patients are observed for 28 days (screening and randomization up to 1 day, treatment for 5 days, follow-up till 28th day).

During the study, six visits are planned: on days 1, 3, 6, 10, 21, and 28 (visits 1, 2, 3, 4, 5, and 6). Visits 1, 3, and 4 are in person (visits to the patient or visits to the medical center) when the physician examines the patient and monitors EPD records. At visit 3, the patient's adherence to treatment is assessed and laboratory tests are performed. Visits 2, 5 and 6 are phone surveys to determine the patient's condition, presence/absence of complaints. In case of worsening of disease duration, the physician makes an extra visit. Patients with COVID-19 progression to more severe form as well as hospitalized patients are considered as reaching the study endpoints and terminate participation in the study ahead of schedule. The therapeutic approach is determined by the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)".

During the study, paracetamol and medicines for the treatment of concomitant diseases are allowed except for those specified in the list of prohibited drugs.

• Study Type: Interventional
• Enrollment (Actual): 813
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Mikhail Putilovskiy, MD, PhD; Phone Number: 302 +74952761571; Email: PutilovskiyMA@materiamedica.ru

Study Locations

• Russian Federation
  • Belgorod, Russian Federation, 308000
    • Belgorod State National Research University, Department of Hospital Therapy
  • Ekaterinburg, Russian Federation, 620137
    • Central City Hospital # 7
  • Ivanovo, Russian Federation, 153025
    • Ivanovo clinical hospital named after Kuvaevs/Polyclinic #10
  • Kazan, Russian Federation, 420012
    • Kazan State Medical University
  • Kazan, Russian Federation, 420012
    • Kazan State Medical University, Department of Propedeutics of Internal Diseases named after prof. S.S. Zimnitsky
  • Kirov, Russian Federation, 610027
    • Kirov State Medical University, Hospital Therapy Department
  • Krasnodar, Russian Federation, 350063
    • Kuban State Medical University, Infectious Diseases and Phthisiopulmonology
  • Nizhniy Novgorod, Russian Federation, 603140
    • Clinical hospital "RZD-Medicine" of the city of Nizhny Novgorod
  • Novosibirsk, Russian Federation, 630051
    • City Clinical Hospital # 2
  • Penza, Russian Federation, 440067
    • Clinical Hospital # 4
  • Perm, Russian Federation, 614070
    • LLC "Professor's clinic"
  • Pyatigorsk, Russian Federation, 357502
    • LLC "Ultrasound Clinic 4D"
  • Ryazan, Russian Federation, 390039
    • Ryazan State Medical University named after Academician I.P. Pavlova
  • Saint Petersburg, Russian Federation, 194156
    • LLC "Energy of Health"
  • Saint Petersburg, Russian Federation, 190121
    • LLC "BioTechService"
  • Saint Petersburg, Russian Federation, 193312
    • City Polyclinic # 25 of the Nevsky District
  • Saint Petersburg, Russian Federation, 196143
    • LLC "Research Center Eco-Safety"
  • Saint Petersburg, Russian Federation, 196158
    • LLC "Clinic Zvezdnaya"
  • Saint Petersburg, Russian Federation, 199406
    • LLC "Meili"
  • Saint Petersburg, Russian Federation, 97762
    • City polyclinic # 74
  • Saint Petersburg, Russian Federation, 194356
    • LLC "Medical Clinic"
  • Saint Petersburg, Russian Federation, 198207
    • City Polyclinic # 43
  • Saint Petersburg, Russian Federation, 192071
    • City clinic # 44
  • Saint Petersburg, Russian Federation, 194291
    • LLC "Strategic medical systems"
  • Saint Petersburg, Russian Federation, 196158
    • JSC "North-West Center for Evidence-Based Medicine"
  • Saint Petersburg, Russian Federation, 198412
    • Lomonosov Interdistrict Hospital named after I.N. Yudchenko
  • Saint Petersburg, Russian Federation, 199106
    • City Intercession Hospital
  • Samara, Russian Federation, 443056
    • Samara City Hospital # 4
  • Saratov, Russian Federation, 410012
    • Saratov State Medical University named after V. I. Razumovsky
  • Saratov, Russian Federation, 410005
    • LLC "Center for DNA Research"
  • Stavropol, Russian Federation, 355000
    • LLC "Scientific Medical Center for General Therapy and Pharmacology"
  • Tver, Russian Federation, 170100
    • Tver State Medical University
  • Ufa, Russian Federation, 450008
    • Bashkir State Medical University, Internal Medicine Department
  • Voronezh, Russian Federation, 394066
    • Voronezh Regional Clinical Hospital # 1
  • Yaroslavl, Russian Federation, 150040
    • Central city hospital
  • Yaroslavl, Russian Federation, 150040
    • LLC "Medical Center for Diagnostics and Prevention Plus"

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male and female patients aged 18-75 years old.
2. Diagnosis of new coronavirus infection COVID-19 based on medical examination: axillary temperature >37.5°C, upper respiratory infection symptoms, SpO2 ≥ 95%, no symptoms of moderate or severe forms.
3. The minimal baseline score for COVID-19-related symptoms defined as follows: at least two symptoms with a score of 2 or higher, with the exception of taste and smell where subjects may have a score of 1 or higher, and the absence of shortness of breath (difficulty breathing).
4. Positive rapid test for for SARS-CoV-2 (COVID-19).
5. The first 24 hours from the disease onset.
6. Patients giving their consent to use reliable contraception during the study.
7. Signed patient information sheet (informed consent form).

Exclusion Criteria:

1. Moderate and severe COVID-19.
2. The first four weeks after any vaccination/revaccination, including against COVID-19, influenza, pneumococcal and other infections.
3. Suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.).
4. Patients requiring medications prohibited within the study.
5. Medical history of or previously diagnosed primary and secondary immunodeficiency.
6. Medical history/suspicion of oncology of any localization (except for benign neoplasms).
7. Exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in the clinical study.
8. Malabsorption syndrome, including congenital or acquired lactase or disaccharidase deficiency, galactosemia.
9. Allergy/ hypersensitivity to any of the components of the medications used in the treatment.
10. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial.
11. Use of medications listed in "Prohibited concomitant therapy" within 4 weeks before the study entry.
12. Patients who, from the investigator's point of view, will fail to comply with the requirements of the trial or with the intake regimen of the study drugs.
13. Medical history of mental diseases, alcoholism or drug abuse which, according to the investigator's opinion, will interfere with the study procedures.
14. Participation in other clinical trials within 3 months prior to enrollment in this study.
15. The patient is related to the study center staff directly involved in the trial or is the immediate relative of the investigator. 'Immediate relative' means husband/wife, parents, children, brother/sister regardless of whether they are natural or adopted.
16. The patient works for OOO "NPF "MATERIA MEDICA HOLDING" i.e. is the company's employee, part-time employee under contract or appointed official in charge of the trial, or their immediate family.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Raphamin; Tablet for oral use.	Drug: Raphamin; Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.
Placebo Comparator: Placebo; Tablet for oral use.	Drug: Placebo; Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of COVID-19 progression to a more severe form	Severity of COVID-19 is assessed in accordance with criteria presented in the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)".	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to sustained clinical recovery after new coronavirus disease COVID-19.	Sustained clinical recovery is a sustained improvement of clinical symptoms for at least 4 consecutive days. The day of improvement is considered the first of these 4 days. Criteria for improvement of clinical symptoms (according to the scoring system "Assessment of 14 Common COVID-19-Related Symptoms") are defined as follows: a score of 1 or 0 (for stuffy or runny nose, sore throat, low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, nausea, diarrhea);; a score 0 (for shortness of breath/difficulty breathing and vomiting);; a score no more than 2 (for cough);; no new symptoms with a score of 1 or 0;; axillary temperature ≤37.3°С.	28 days
Percentage of hospitalized patients	Based on the medical records.	28 days

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to COVID-19 progression to a more severe form	Severity of COVID-19 will be assessed in accordance with the criteria presented in the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)".	28 days
Percentage of patients with negative PCR test for SARS-CoV-2	Based on the medical records.	On days 6 and 10
Adverse events during the treatment, their severity, causality, outcome.	Based on the medical records.	From day 1 to day 6
Changes in Vital Signs: Pulse Rate/Heart Rate in Beats per minute (bpm)	The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in visits 1 and 3 (on days 1 and 6).	From day 1 to day 6
Changes in Vital Signs: Respiration Rate/Breathing Rate in breaths per minute.	Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in visits 1 and 3 (on days 1 and 6).	From day 1 to day 6
Changes in Vital Signs: Blood Pressure in units of millimeters of mercury (mmHg).	Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in visits 1 and 3 (on days 1 and 6).	From day 1 to day 6
Percentage of patients with clinically significant abnormal laboratory tests.	Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.	From day 1 to day 6

Collaborators and Investigators

• Sponsor: Materia Medica Holding

Study record dates

Study Major Dates

• Study Start (Actual): April 29, 2022
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: May 4, 2022
• First Submitted That Met QC Criteria: May 4, 2022
• First Posted (Actual): May 6, 2022

Study Record Updates

• Last Update Posted (Actual): August 16, 2023
• Last Update Submitted That Met QC Criteria: August 15, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Coronavirus Infections
• Other Study ID Numbers: MMH-407-006

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No